Cargando…

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

The relationship between baseline fasting C‐peptide (FCP) and glucose control was examined in insulin‐naïve people with type 2 diabetes inadequately controlled with oral antihyperglycaemic drugs commencing basal insulin glargine 300 U/mL (Gla‐300) or 100 U/mL (Gla‐100) in the absence of sulfonylurea...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolli, Geremia B., Landgraf, Wolfgang, Bosnyak, Zsolt, Melas‐Melt, Lydie, Home, Philip D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496109/
https://www.ncbi.nlm.nih.gov/pubmed/32314521
http://dx.doi.org/10.1111/dom.14065
_version_ 1783583024930095104
author Bolli, Geremia B.
Landgraf, Wolfgang
Bosnyak, Zsolt
Melas‐Melt, Lydie
Home, Philip D.
author_facet Bolli, Geremia B.
Landgraf, Wolfgang
Bosnyak, Zsolt
Melas‐Melt, Lydie
Home, Philip D.
author_sort Bolli, Geremia B.
collection PubMed
description The relationship between baseline fasting C‐peptide (FCP) and glucose control was examined in insulin‐naïve people with type 2 diabetes inadequately controlled with oral antihyperglycaemic drugs commencing basal insulin glargine 300 U/mL (Gla‐300) or 100 U/mL (Gla‐100) in the absence of sulfonylurea/glinides. Participants with FCP measurement from the EDITION 3 trial (n = 867) were stratified according to baseline FCP (≤0.40, >0.40‐1.20, >1.20 nmol/L); 11.0%, 70.9% and 18.1% contributed to each group. Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 26 weeks. Glycaemic control (HbA1c, FPG) at 26 weeks was similar in each FCP group between insulins. However, end‐of‐study insulin dose was greater with higher FCP for both insulins. More people with lower baseline FCP experienced hypoglycaemia with both insulins, but with numerically lower incidence for Gla‐300 versus Gla‐100 across all FCP groups for all definitions (time periods and levels) of hypoglycaemia. This suggests that Gla‐300 might be particularly advantageous for people who are at higher risk of hypoglycaemia.
format Online
Article
Text
id pubmed-7496109
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-74961092020-09-25 Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial Bolli, Geremia B. Landgraf, Wolfgang Bosnyak, Zsolt Melas‐Melt, Lydie Home, Philip D. Diabetes Obes Metab Brief Reports The relationship between baseline fasting C‐peptide (FCP) and glucose control was examined in insulin‐naïve people with type 2 diabetes inadequately controlled with oral antihyperglycaemic drugs commencing basal insulin glargine 300 U/mL (Gla‐300) or 100 U/mL (Gla‐100) in the absence of sulfonylurea/glinides. Participants with FCP measurement from the EDITION 3 trial (n = 867) were stratified according to baseline FCP (≤0.40, >0.40‐1.20, >1.20 nmol/L); 11.0%, 70.9% and 18.1% contributed to each group. Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 26 weeks. Glycaemic control (HbA1c, FPG) at 26 weeks was similar in each FCP group between insulins. However, end‐of‐study insulin dose was greater with higher FCP for both insulins. More people with lower baseline FCP experienced hypoglycaemia with both insulins, but with numerically lower incidence for Gla‐300 versus Gla‐100 across all FCP groups for all definitions (time periods and levels) of hypoglycaemia. This suggests that Gla‐300 might be particularly advantageous for people who are at higher risk of hypoglycaemia. Blackwell Publishing Ltd 2020-05-29 2020-09 /pmc/articles/PMC7496109/ /pubmed/32314521 http://dx.doi.org/10.1111/dom.14065 Text en © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Reports
Bolli, Geremia B.
Landgraf, Wolfgang
Bosnyak, Zsolt
Melas‐Melt, Lydie
Home, Philip D.
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
title Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
title_full Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
title_fullStr Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
title_full_unstemmed Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
title_short Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial
title_sort hypoglycaemia risk with insulin glargine 300 u/ml compared with glargine 100 u/ml across different baseline fasting c‐peptide levels in insulin‐naïve people with type 2 diabetes: a post hoc analysis of the edition 3 trial
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496109/
https://www.ncbi.nlm.nih.gov/pubmed/32314521
http://dx.doi.org/10.1111/dom.14065
work_keys_str_mv AT bolligeremiab hypoglycaemiariskwithinsulinglargine300umlcomparedwithglargine100umlacrossdifferentbaselinefastingcpeptidelevelsininsulinnaivepeoplewithtype2diabetesaposthocanalysisoftheedition3trial
AT landgrafwolfgang hypoglycaemiariskwithinsulinglargine300umlcomparedwithglargine100umlacrossdifferentbaselinefastingcpeptidelevelsininsulinnaivepeoplewithtype2diabetesaposthocanalysisoftheedition3trial
AT bosnyakzsolt hypoglycaemiariskwithinsulinglargine300umlcomparedwithglargine100umlacrossdifferentbaselinefastingcpeptidelevelsininsulinnaivepeoplewithtype2diabetesaposthocanalysisoftheedition3trial
AT melasmeltlydie hypoglycaemiariskwithinsulinglargine300umlcomparedwithglargine100umlacrossdifferentbaselinefastingcpeptidelevelsininsulinnaivepeoplewithtype2diabetesaposthocanalysisoftheedition3trial
AT homephilipd hypoglycaemiariskwithinsulinglargine300umlcomparedwithglargine100umlacrossdifferentbaselinefastingcpeptidelevelsininsulinnaivepeoplewithtype2diabetesaposthocanalysisoftheedition3trial